Relapsed/refractory multiple myeloma (RRMM): The relevance of adding a new MoA

Multiple myeloma is highly heterogeneous from diagnosis, which makes it a complex disease.
Dr Fredrik Schjesvold explores the importance of adding a new Mechanism of Action (MoA) in relapsed/refectory multiple myeloma (RRMM) focusing on:
The heterogeneity at diagnosis, as the heterogenic clones vary in their sensitivity to different treatments, and discusses genomic aberrations and drug sensitivity
The impact of changing and adding drug classes in relapse treatment
Clinical Takeaways
Multiple myeloma is a highly heterogeneous disease from diagnosis
The heterogeneic clones vary in their sensitivity to different treatments. Therefore, combinations are preferable
Each new treatment should preferably include drugs with novel mechanisms of action, which is more important when multiple myeloma becomes refractory rather than just exposed
This is part 2 of a 3-part video series.
Watch part 1 to see Dr Elena Zamagni summarise the unmet medical needs in earlier relapses in multiple myeloma - cor2ed.com/lym...
Watch part 2 to see Dr Joseph Mikhael discuss current best practices in treating patients with multiple myeloma - cor2ed.com/lym...
Read more about the experts and download the accompanying slide sets on our website: cor2ed.com/lym...
Subscribe to the COR2ED RUclips channel to stay up-to-date with new medical education content as it’s released.
Come and find LYMPHOMA & MYELOMA CONNECT on social media
Follow us on LinkedIn: / lymphoma-myeloma-connect
Follow us on X: x.com/LYM_MM_C...
This content is intended for healthcare professionals only. The medical experts in this video are expressing their own views and not those of COR2ED, supporters, or their institution. This programme is supported by an Independent Medical Education Grant from Menarini Stemline Oncology. This video was developed by cor2ed.com
Publication date: September 2024